Xenetic Biosciences (XBIO) Total Non-Current Liabilities (2014 - 2021)
Xenetic Biosciences' (XBIO) quarterly Total Non-Current Liabilities came in at $958214.0 in Q2 2021, up 20.05% on a QoQ basis from $798191.0 in Q1 2021.
Xenetic Biosciences (XBIO) Total Non-Current Liabilities (2014 - 2021) Analysis & Trends
Xenetic Biosciences (XBIO) has 8 years of Total Non-Current Liabilities data on file, last reported at $958214.0 in Q2 2021.
- Quarterly Total Non-Current Liabilities changed N/A year-over-year to $958214.0 in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $958214.0 (changed N/A YoY) and the FY2020 annual result came in at $936928.0, changed N/A from the prior year.
- Total Non-Current Liabilities improved to $958214.0 in Q2 2021, from $798191.0 in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $5.2 million in Q2 2019 to a low of $798191.0 in Q1 2021.
- A 5-year average of $3.7 million and a median of $4.9 million in 2017 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 1.62% in 2017, down 62.97% in 2017.
- Tracing XBIO's Total Non-Current Liabilities over 5 years: stood at $4.9 million in 2017, then retreated by 7.07% to $4.5 million in 2018, then advanced by 15.89% to $5.2 million in 2019, then sank by 82.11% to $936928.0 in 2020, then climbed by 2.27% to $958214.0 in 2021.
- The last three Total Non-Current Liabilities figures came in at $958214.0 (Q2 2021), $798191.0 (Q1 2021), and $936928.0 (Q4 2020), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.75 Bn | 130.90 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.96 Bn | 77.96 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.98 Bn | 59.80 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 56.33 Bn | 51.19 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.03 Bn | 36.93 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.56 Bn | 28.25 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.74 Bn | 9.35 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.32 Bn | 26.49 Bn | - | 9.32 Bn |
| 10 | Xenetic Biosciences | 8.26 Mn | 1.79 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 958,214.00 |
| Mar 31, 2021 | 798,191.00 |
| Dec 31, 2020 | 936,928.00 |
| Jun 30, 2019 | 5.24 Mn |
| Mar 31, 2019 | 4.92 Mn |
| Dec 31, 2018 | 4.52 Mn |
| Dec 31, 2017 | 4.86 Mn |
| Sep 30, 2017 | 5.08 Mn |
| Jun 30, 2017 | 4.92 Mn |
| Mar 31, 2017 | 4.91 Mn |
| Dec 31, 2016 | 4.78 Mn |
| Sep 30, 2016 | 7.89 Mn |
| Jun 30, 2016 | 6.72 Mn |
| Mar 31, 2016 | 13.27 Mn |
| Dec 31, 2015 | 10.26 Mn |
| Sep 30, 2015 | 9.03 Mn |
| Jun 30, 2015 | 6.39 Mn |
| Mar 31, 2015 | 5.78 Mn |
| Dec 31, 2014 | 5.78 Mn |
| Sep 30, 2014 | 5.24 Mn |